{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:14:49Z","timestamp":1773404089242,"version":"3.50.1"},"reference-count":42,"publisher":"Japanese Society of Internal Medicine","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,7,1]]},"DOI":"10.2169\/internalmedicine.0743-22","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T22:10:02Z","timestamp":1668550202000},"page":"1895-1905","source":"Crossref","is-referenced-by-count":4,"title":["Paraganglioma with High Levels of Dopamine, Dopa Decarboxylase Suppression, Dopamine \u03b2-hydroxylase Upregulation and Intra-tumoral Melanin Accumulation: A Case Report with a Literature Review"],"prefix":"10.2169","volume":"62","author":[{"given":"Masahiro","family":"Nezu","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes, Yamanashi Central Hospital, Japan"},{"name":"Genome Analysis Center, Yamanashi Central Hospital, Japan"},{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Hirotsu","sequence":"additional","affiliation":[{"name":"Genome Analysis Center, Yamanashi Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Amemiya","sequence":"additional","affiliation":[{"name":"Genome Analysis Center, Yamanashi Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Tateno","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichi","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Yamanashi Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Yamanashi Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Genome Analysis Center, Yamanashi Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Hosaka","sequence":"additional","affiliation":[{"name":"Department of Urology, Yamanashi Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance","family":"Chik","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Oyama","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yamanashi Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Omata","sequence":"additional","affiliation":[{"name":"Genome Analysis Center, Yamanashi Central Hospital, Japan"},{"name":"The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99: 1915-1942, 2014.","DOI":"10.1210\/jc.2014-1498"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gupta G, Pacak K, Committee AAS; AACE Adremnal Scientific Committee. Precision medicine: an update on genotype\/biochemical phenotype relationships in pheochromocytoma\/paraganglioma patients. Endocr Pract 23: 690-704, 2017.","DOI":"10.4158\/EP161718.RA"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Dubois LA, Gray DK. Dopamine-secreting pheochromocytomas: in search of a syndrome. World J Surg 29: 909-913, 2005.","DOI":"10.1007\/s00268-005-7860-7"},{"key":"4","unstructured":"4. Foo SH, Chan SP, Ananda V, Rajasingam V. Dopamine-secreting phaeochromocytomas and paragangliomas: clinical features and management. Singapore Med J 51: e89-93, 2010."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Eisenhofer G, Goldstein DS, Sullivan P, et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab 90: 2068-2075, 2005.","DOI":"10.1210\/jc.2004-2025"},{"key":"6","unstructured":"6. Yasunari K, Kohno M, Yoshikawa J. A dopamine-secreting pheochromocytoma. Am J Med 106: 599-600, 1999."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Karagiannis A, Mikhailidis DP, Athyros VG, Harsoulis F. Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer 14: 935-956, 2007.","DOI":"10.1677\/ERC-07-0142"},{"key":"8","unstructured":"8. Fishbein L, Leshchiner I, Walter V, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31: 181-193, 2017."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Grouzmann E, Matter M, Bilz S, et al. Monoamine oxidase A down-regulation contributes to high metanephrine concentration in pheochromocytoma. J Clin Endocrinol Metab 97: 2773-2781, 2012.","DOI":"10.1210\/jc.2012-1557"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hirotsu Y, Nakagomi H, Sakamoto I, et al. Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer. Mol Genet Genomic Med 3: 459-466, 2015.","DOI":"10.1002\/mgg3.157"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nezu M, Hirotsu Y, Amemiya K, et al. A case of juvenile-onset pheochromocytoma with <i>KIF1B<\/i> p.V1529M germline mutation. Endocr J 69: 705-716, 2022.","DOI":"10.1507\/endocrj.EJ21-0475"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kimura N, Takayanagi R, Takizawa N, et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer 21: 405-414, 2014.","DOI":"10.1530\/ERC-13-0494"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Miyamoto S, Yoshida Y, Ozeki Y, et al. Dopamine-secreting pheochromocytoma and paraganglioma. J Endocr Soc 5: bvab163, 2021.","DOI":"10.1210\/jendso\/bvab163"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yasunari K, Kohno M, Minami M, et al. A dopamine-secreting pheochromocytoma. J Cardiovasc Pharmacol 36 (Suppl 2): S75-S77, 2000.","DOI":"10.1097\/00005344-200000006-00016"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Matsuda Y, Kimura N, Yoshimoto T, et al. Dopamine-secreting paraganglioma in the retroperitoneum. Endocr Pathol 28: 36-40, 2017.","DOI":"10.1007\/s12022-016-9457-0"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Maison N, Korpershoek E, Eisenhofer G, Robledo M, de Krijger R, Beuschlein F. Somatic RET mutation in a patient with pigmented adrenal pheochromocytoma. Endocrinol Diabetes Metab Case Rep 2016: 150117, 2016.","DOI":"10.1530\/EDM-15-0117"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kakkar A, Kaur K, Kumar T, et al. Pigmented pheochromocytoma: an unusual variant of a common tumor. Endocr Pathol 27: 42-45, 2016.","DOI":"10.1007\/s12022-015-9407-2"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Petramala L, Cotesta D, Filetti S, Letizia C. Pigmented &apos;black&apos; cardiac paraganglioma in a patient with a novel germ-line SDHD mutation. Eur J Cardiothorac Surg 35: 189, 2009.","DOI":"10.1016\/j.ejcts.2008.10.007"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Miraldi F, Taffon C, Toscano M, Barretta A. Black cardiac paraganglioma in a multiple paraganglioma syndrome. Eur J Cardiothorac Surg 32: 940-942, 2007.","DOI":"10.1016\/j.ejcts.2007.08.026"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Handa U, Khullar U, Mohan H, Pigmented pheochromocytoma. report of a case with diagnosis by fine needle aspiration. Acta Cytol 49: 421-423, 2005.","DOI":"10.1159\/000326176"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Dundr P, Dudorkinova D, Povysil C, et al. Pigmented composite paraganglioma-ganglioneuroma of the urinary bladder. Pathol Res Pract 199: 765-769, 2003.","DOI":"10.1078\/0344-0338-00495"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Langner C, Hoffmann JG, de Geeter P, Rompel R, Ruschoff J. [Pigmented pheochromocytoma. Case report with immunohistochemical and electron microscopic characterization]. Pathologe 22: 276-280, 2001.","DOI":"10.1007\/s002920100465"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Chetty R, Clark SP, Taylor DA. Pigmented pheochromocytomas of the adrenal medulla. Hum Pathol 24: 420-423, 1993.","DOI":"10.1016\/0046-8177(93)90091-T"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Timmers HJ, Kozupa A, Eisenhofer G, et al. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 92: 779-786, 2007.","DOI":"10.1210\/jc.2006-2315"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Bourdeau I, Grunenwald S, Burnichon N, et al. A <i>SDHC<\/i> founder mutation causes paragangliomas (PGLs) in the French Canadians: new insights on the <i>SDHC<\/i>-related PGL. J Clin Endocrinol Metab 101: 4710-4718, 2016.","DOI":"10.1210\/jc.2016-1665"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Brownstein MJ, Hoffman BJ. Neurotransmitter transporters. Recent Prog Horm Res 49: 27-42, 1994.","DOI":"10.1016\/B978-0-12-571149-4.50006-4"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Hein L. Adrenoceptors and signal transduction in neurons. Cell Tissue Res 326: 541-551, 2006.","DOI":"10.1007\/s00441-006-0285-2"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Gonzalez-Lopez E, Vrana KE. Dopamine beta-hydroxylase and its genetic variants in human health and disease. J Neurochem 152: 157-181, 2020.","DOI":"10.1111\/jnc.14893"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. van Berkel A, Rao JU, Lenders JW, et al. Semiquantitative <sup>123<\/sup>I-metaiodobenzylguanidine scintigraphy to distinguish pheochromocytoma and paraganglioma from physiologic adrenal uptake and its correlation with genotype-dependent expression of catecholamine transporters. J Nucl Med 56: 839-846, 2015.","DOI":"10.2967\/jnumed.115.154815"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Ren LQ, Chen M, Hultborn H, Guo S, Zhang Y, Zhang M. Heterogenic distribution of aromatic L-amino acid decarboxylase neurons in the rat spinal cord. Front Integr Neurosci 11: 31, 2017.","DOI":"10.3389\/fnint.2017.00031"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Cellini B, Montioli R, Oppici E, Voltattorni CB. Biochemical and computational approaches to improve the clinical treatment of dopa decarboxylase-related diseases: an overview. Open Biochem J 6: 131-138, 2012.","DOI":"10.2174\/1874091X01206010131"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Eisenhofer G, Tian H, Holmes C, Matsunaga J, Roffler-Tarlov S, Hearing VJ. Tyrosinase: a developmentally specific major determinant of peripheral dopamine. FASEB J 17: 1248-1255, 2003.","DOI":"10.1096\/fj.02-0736com"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Rios M, Habecker B, Sasaoka T, et al. Catecholamine synthesis is mediated by tyrosinase in the absence of tyrosine hydroxylase. J Neurosci 19: 3519-3526, 1999.","DOI":"10.1523\/JNEUROSCI.19-09-03519.1999"},{"key":"34","unstructured":"34. Kuchel O, Buu NT, Edwards DJ. Alternative catecholamine pathways after tyrosine hydroxylase inhibition in malignant pheochromocytoma. J Lab Clin Med 115: 449-453, 1990."},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. van Veen S, Sorensen DM, Holemans T, Holen HW, Palmgren MG, Vangheluwe P. Cellular function and pathological role of ATP13A2 and related P-type transport ATPases in Parkinson&apos;s disease and other neurological disorders. Front Mol Neurosci 7: 48, 2014.","DOI":"10.3389\/fnmol.2014.00048"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Ramirez A, Heimbach A, Grundemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in <i>ATP13A2<\/i>, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38: 1184-1191, 2006.","DOI":"10.1038\/ng1884"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Park JS, Blair NF, Sue CM. The role of ATP13A2 in Parkinson&apos;s disease: clinical phenotypes and molecular mechanisms. Mov Disord 30: 770-779, 2015.","DOI":"10.1002\/mds.26243"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Daniel G, Musso A, Tsika E, et al. \u03b1-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson&apos;s disease occurs independent of ATP13A2 (PARK9). Neurobiol Dis 73: 229-243, 2015.","DOI":"10.1016\/j.nbd.2014.10.007"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Yamazaki Y, Gao X, Pecori A, et al. Recent advances in histopathological and molecular diagnosis in pheochromocytoma and paraganglioma: challenges for predicting metastasis in individual patients. Front Endocrinol (Lausanne) 11: 587769, 2020.","DOI":"10.3389\/fendo.2020.587769"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Thompson LD. Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26: 551-566, 2002.","DOI":"10.1097\/00000478-200205000-00002"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Haden T, Zuberek M, Pokala N. Forty-three-year-old female with dopamine secreting pheochromocytoma of the adrenal gland. Case Rep Urol 2017: 1736326, 2017.","DOI":"10.1155\/2017\/1736326"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Eisenhofer G, Lenders JW, Siegert G, et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer 48: 1739-1749, 2012.","DOI":"10.1016\/j.ejca.2011.07.016"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/13\/62_0743-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:32:46Z","timestamp":1715315566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/13\/62_0743-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":42,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0743-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]},"article-number":"0743-22"}}